When ibogaine is metabolized in the liver, it converts primarily into noribogaine — a distinct compound that persists in the body for days to weeks and is increasingly recognized as the key driver of ibogaine's long-term anti-addictive and mood-stabilizing effects. Understanding noribogaine separately from ibogaine helps explain why therapeutic outcomes often unfold gradually, long after the acute psychedelic experience ends.

What exactly is noribogaine and how is it formed?

Noribogaine (also called 12-hydroxyibogamine) is the principal active metabolite of ibogaine. After oral ingestion of ibogaine, the liver enzyme CYP2D6 demethylates ibogaine at the 12-position methoxy group, producing noribogaine. This conversion begins within the first hour of ingestion and continues as ibogaine is cleared from the bloodstream.

While ibogaine itself typically has a plasma half-life of roughly 4–7 hours, noribogaine's half-life ranges from approximately 28 to 49 hours in clinical studies — and in some individuals measurable levels persist for several weeks. Research published in Clinical Pharmacology in Drug Development (Glue et al., 2015) confirmed this extended pharmacokinetic profile in healthy volunteers receiving oral noribogaine directly, providing a cleaner window into the compound's standalone behavior.

Critically, how much noribogaine a person produces depends heavily on their CYP2D6 genotype. Poor metabolizers convert ibogaine slowly, accumulating more ibogaine and less noribogaine. Ultra-rapid metabolizers may produce noribogaine faster. This genetic variability is one reason ibogaine experiences and outcomes differ substantially between individuals.

How does noribogaine's pharmacology differ from ibogaine?

Ibogaine and noribogaine share some receptor targets but diverge in important ways:

  • Serotonin transporter (SERT): Noribogaine is a significantly more potent serotonin reuptake inhibitor than ibogaine. Baumann et al. (2001) demonstrated that noribogaine produced sustained elevations in extracellular serotonin in the rat nucleus accumbens, a region central to mood and reward processing. This SSRI-like activity may underlie the mood-stabilizing and anti-depressant effects reported by patients in the weeks following treatment.
  • Kappa-opioid receptor (KOR): Noribogaine shows meaningful activity at kappa-opioid receptors, which play a role in stress response, dysphoria, and addiction vulnerability. Modulation of KOR signaling is an active target in addiction pharmacology research.
  • Sigma-2 receptors: Both compounds interact with sigma receptors, which are implicated in neuroplasticity and cellular stress responses.
  • hERG potassium channels: Like ibogaine, noribogaine prolongs the cardiac QT interval by blocking hERG channels — though early data suggests noribogaine may carry a somewhat different cardiac risk profile than ibogaine itself. This remains an area of active investigation.
  • NMDA receptors: Noribogaine has moderate antagonist activity at NMDA receptors, which may contribute to its effects on memory reconsolidation and learned addiction behaviors.

Notably, noribogaine does not share ibogaine's strong dissociative or hallucinogenic properties, suggesting the visionary psychedelic experience associated with ibogaine treatment is primarily attributable to ibogaine itself, while noribogaine handles a quieter but potentially equally important neurochemical reset afterward.

What does noribogaine do to addiction neurobiology long-term?

The persistence of noribogaine in plasma and tissues positions it as a kind of sustained-release pharmacotherapy following a single ibogaine dose. Several mechanisms have been proposed for its long-term anti-addictive action:

  • Opioid withdrawal attenuation: Noribogaine demonstrates agonist activity at mu-opioid receptors — enough to blunt withdrawal symptoms without producing strong euphoria. Mash et al. (2016) documented rapid suppression of opioid withdrawal signs in patients treated at an observational clinic in St. Kitts, with sustained abstinence in a significant subset at 30-day follow-up.
  • Reward pathway normalization: Extended serotonergic activity in the nucleus accumbens may gradually recalibrate the reward deficit state characteristic of post-acute withdrawal syndrome (PAWS), reducing the anhedonia and craving that drive relapse.
  • Neuroplasticity: Preclinical work suggests ibogaine and noribogaine may upregulate glial cell line-derived neurotrophic factor (GDNF), a protein involved in neuronal repair and dopamine system maintenance. Research from the Bhave and Bhatt groups has pointed to GDNF as a candidate mechanism for durable anti-addictive effects.
  • Fear memory disruption: NMDA receptor antagonism during the noribogaine window may interfere with reconsolidation of drug-associated memories, potentially weakening cue-triggered cravings over time.
Cardiac Safety Note: Noribogaine, like ibogaine, prolongs the QTc interval on electrocardiogram. This effect has been confirmed in human dose-escalation trials (Glue et al., 2015). QT prolongation can predispose individuals to potentially fatal arrhythmias, particularly torsades de pointes. Any clinical use of ibogaine or noribogaine requires cardiac screening, continuous ECG monitoring, and electrolyte management. Ibogaine is Schedule I in the US; noribogaine's legal status varies by jurisdiction. Neither should be self-administered.

Has noribogaine been studied as a standalone drug?

Yes — and this is a scientifically significant development. Because noribogaine lacks ibogaine's intense psychedelic properties and may be more pharmacologically predictable, several researchers and companies have explored it as a standalone therapeutic candidate for opioid use disorder.

Demerx Inc. conducted Phase 1 and Phase 2a clinical trials of oral noribogaine in healthy volunteers and opioid-dependent patients. The Glue et al. (2015) ascending-dose study established preliminary safety and pharmacokinetic parameters in humans. A subsequent Phase 2a trial examined noribogaine's capacity to reduce opioid withdrawal severity, with results suggesting dose-dependent suppression of withdrawal symptoms compared to placebo.

These trials stalled before Phase 3, but they provided a foundational dataset demonstrating that noribogaine could be administered to humans in a controlled setting with measurable, quantifiable effects — a critical step toward eventual regulatory consideration. Researchers currently continue exploring noribogaine analogs and derivative compounds as part of broader psychedelic-adjacent drug development programs.

What are the implications for understanding ibogaine treatment outcomes?

Recognizing noribogaine's role reframes how clinicians and patients should interpret the ibogaine treatment timeline. The dramatic 24–36 hour acute ibogaine experience — with its intense visionary and introspective phases — is only the first chapter. The weeks that follow, during which noribogaine slowly clears, represent a distinct pharmacological window sometimes called the "afterglow" period.

During this window, patients commonly report reduced craving, elevated mood, improved sleep, and increased emotional clarity. Structured integration support, counseling, and lifestyle changes implemented during this period may be especially impactful, because the neurochemical environment created by noribogaine could make behavioral learning and habit reconsolidation more accessible. Researchers increasingly argue that treatment protocols that ignore the noribogaine phase are failing to capitalize on its therapeutic potential.

Frequently Asked Questions

No. Noribogaine does not produce the strong dissociative or visionary hallucinations associated with ibogaine. At the doses studied in human trials, participants remained alert and oriented. Its effects are more comparable to a combination of a mild serotonin reuptake inhibitor and a partial opioid agonist, without meaningful psychedelic properties.
Human pharmacokinetic data indicate noribogaine has a half-life of roughly 28–49 hours, meaning clinically meaningful levels can persist for one to several weeks after a single ibogaine dose. Individual variation — particularly CYP2D6 genotype — significantly affects both the rate of noribogaine production and clearance.
Both compounds block hERG potassium channels and prolong the QTc interval, which carries arrhythmia risk. Clinical trials of standalone noribogaine confirmed dose-dependent QTc prolongation. Some preclinical data suggest noribogaine's hERG binding profile differs slightly from ibogaine's, but the cardiac risk is still real and cannot be dismissed. Cardiac monitoring is essential in any clinical context.
Ibogaine is Schedule I under the US Controlled Substances Act. Noribogaine itself is not separately scheduled federally, but because it is a metabolite and derivative of a Schedule I substance, its legal status is complex and context-dependent. It is not approved by the FDA as a drug. Anyone considering research or clinical work involving these compounds should consult legal counsel and review DEA scheduling rules carefully.
Researchers hypothesize that effects lasting beyond noribogaine's clearance may reflect durable neuroplastic changes — including upregulation of GDNF, reorganization of reward circuit activity, and weakening of drug-associated memory traces via NMDA receptor modulation. Psychological insight from the ibogaine experience itself, reinforced during integration, likely compounds these biological changes. The full mechanism of long-term benefit remains an active research question.
CYP2D6 pharmacogenomic testing can provide meaningful predictive information. Poor metabolizers will convert ibogaine to noribogaine more slowly, potentially accumulating more ibogaine and experiencing a longer or more intense acute phase. Ultra-rapid metabolizers may have a different exposure profile. Some specialized ibogaine clinics currently incorporate CYP2D6 genotyping into pre-treatment screening, though standardized clinical protocols have not yet been universally adopted.
Demerx completed early-phase human trials of oral noribogaine but the program did not progress to Phase 3. Currently, no noribogaine product is in late-stage FDA trials or close to approval. However, interest in non-hallucinogenic ibogaine derivatives — including noribogaine and compounds like 18-MC — continues within academic and biotech research communities as a strategy to capture therapeutic benefits with a more manageable safety profile.

The science of noribogaine is still maturing, but it has already shifted how researchers conceptualize ibogaine's mechanism of action — from a single acute event to a two-phase pharmacological process. If you are researching ibogaine treatment for yourself or someone you care about, understanding noribogaine's role is essential context. Speak with a physician experienced in addiction medicine, consult a pharmacogeneticist if CYP2D6 status is unknown, and engage a qualified integration therapist to support the full treatment window — not just the acute session. This is especially important given ibogaine's Schedule I status in the US and the cardiac risks that require proper medical supervision.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.